New Zealand markets closed
  • NZX 50

    12,197.15
    +44.95 (+0.37%)
     
  • NZD/USD

    0.6326
    -0.0148 (-2.29%)
     
  • NZD/EUR

    0.5858
    -0.0068 (-1.14%)
     
  • ALL ORDS

    7,771.80
    +43.30 (+0.56%)
     
  • ASX 200

    7,558.10
    +46.50 (+0.62%)
     
  • OIL

    73.35
    -0.04 (-0.05%)
     
  • GOLD

    1,875.40
    -1.20 (-0.06%)
     
  • NASDAQ

    12,573.36
    -229.74 (-1.79%)
     
  • FTSE

    7,901.80
    +81.64 (+1.04%)
     
  • Dow Jones

    33,926.01
    -127.89 (-0.38%)
     
  • DAX

    15,476.43
    -32.77 (-0.21%)
     
  • Hang Seng

    21,660.47
    -297.93 (-1.36%)
     
  • NIKKEI 225

    27,509.46
    +107.36 (+0.39%)
     
  • NZD/JPY

    83.3070
    +0.0940 (+0.11%)
     

Illumina Third Quarter 2022 Earnings: EPS Misses Expectations

Illumina (NASDAQ:ILMN) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$1.12b (flat on 3Q 2021).

  • Net loss: US$3.82b (down from US$317.0m profit in 3Q 2021).

  • US$24.31 loss per share (down from US$2.09 profit in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Illumina EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Illumina's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here